How long does it take to implement and validate an eQMS?

1No regulation sets a timetable.

Part 11, Annex 11 and FDA’s computer software assurance guidance say what must be true before an eQMS is used, not how long getting there should take. Part 11 requires validation of systems that hold required records.¹ Annex 11 says “the application should be validated”, with the extent based on “a justified and documented risk assessment”.² For medical device makers, FDA notes that ISO 13485 requires the approach to software validation to be “proportionate to the risk associated with the use of the software”.³

So implementation time is the scope you take on multiplied by the effort each part needs, and the rules let you scale that effort to risk. The rest of this page sets out where the time goes and what lengthens or shortens each part.

2Where the time goes.

The phases draw on Annex 11,² the drug CGMP training requirement,⁴ and Part 11’s requirements for trained users and for certifying electronic signatures to FDA before or at first use.¹⁵ Customisation adds its own obligation: for bespoke or customised systems, Annex 11 expects “the formal assessment and reporting of quality and performance measures for all the life-cycle stages of the system”.²

3Scale validation to risk.

FDA’s guidance on computer software assurance, reissued on 3 February 2026, was written for medical device production and quality management system software and prepared in consultation with FDA’s drugs centre.³ It calls for “a least-burdensome approach, where the burden of validation is no more than necessary to address the risk”.³ Among functions that generally are not high process risk it lists those used in the quality system “for Corrective and Preventive Actions (CAPA) routing, automated logging/tracking of complaints, automated change control management, or automated procedure management”.³

For functions that aren’t high process risk, FDA says manufacturers “may consider using unscripted testing methods such as scenario testing, error-guessing, exploratory testing”, and suggests more rigour, such as scripted testing, for high-risk ones.³ It recommends using “system logs, audit trails, and other data generated and maintained by the software” as evidence, rather than screenshots.³ Its worked example of a nonconformance system shows the split inside one eQMS: initiating a nonconformance gets exploratory testing, the electronic signature function gets scenario testing, and the function that prompts a decision on correcting or removing distributed product is high process risk and gets a detailed scripted protocol.³

For medicines the same principle appears in FDA’s data integrity guidance, which asks for validation “commensurate with the risk posed by the automated system”,⁶ and in Annex 11.² ISPE’s GAMP 5 Second Edition of July 2022 stresses “critical thinking” by experienced subject matter experts in choosing the approach.⁷

4Build on the supplier’s evidence.

FDA suggests starting from what the developer has already done: a manufacturer can use “the software development practices, validation work, and electronic information already performed by developers of the software as the starting point”, and for some lower-risk functions “this may be all the assurance that is needed”.³ Annex 11 asks regulated users to review documentation supplied with off-the-shelf products “to check that user requirements are fulfilled”.² GAMP 5 encourages companies to “maximize supplier involvement to leverage knowledge, experience, and documentation where possible”.⁷

FDA’s example of a software-as-a-service product life cycle management system has the vendor document the changes, testing and test results of each automatic update, and the manufacturer assess each change against its intended use and test what the impact calls for.³ A hosted eQMS brings the same work with every release, so ask how often releases arrive before you commit to a plan.

The draft revision of Annex 11 would add two points. Qualification and validation documentation could be provided by a vendor “in parts or in whole”, with the regulated user “fully accountable” for reviewing and authorising its use, and a system could go into use under a conditional approval where open deficiencies have been assessed as having no impact on product quality, patient safety or data integrity.⁸ These are draft; the Annex 11 in force is the January 2011 version.⁹

5Plan the migration early.

Migration is easy to underestimate. MHRA says “the challenges of migrating data are often underestimated, particularly regarding maintaining the full meaning of the migrated records”.¹⁰ Annex 11 requires validation to check that migrated data “are not altered in value and/or meaning”.² Moving only current documents, their history and open records, and keeping closed paper records retrievable where they are, reduces both the work and the testing.

6How it runs in Seal.

Seal starts with one process. The 48-hour evaluation turns one of your procedures into a working workflow with a validation pack to inspect, and production timing then depends on scope, interfaces, migration and your release requirements; see the QMS. The validation and AI assurance guide sets out the split of work: Seal provides the platform controls and its development, verification and release evidence for the version in scope, which you can reuse where your assessment supports it, and your team owns the intended use, requirements, risk acceptance, qualification of integrations and migrated data, training and production approval.

After go-live, each change identifies its intended use, affected requirements and risks, and applicable automated verification and repeatable UAT checks run when the configuration changes, with results kept against the proposed version. The Veeva Vault QMS comparison sets out how that differs from assessing a supplier’s periodic releases.